Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma

Next Previous
Trial Profile

A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; Fulvestrant (Primary) ; MRT-2359 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Diffuse large B cell lymphoma; HER2 negative breast cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Monte Rosa Therapeutics

Most Recent Events

  • 03 Mar 2026 Status changed from recruiting to active, no longer recruiting.
  • 24 Feb 2026 According to a Monte Rosa Therapeutics media release, the company announced updated, positive clinical data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). The data, being presented at the 2026 ASCO GU Symposium in San Francisco, CA.
  • 24 Feb 2026 Results presented in a Monte Rosa Therapeutics media Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top